Precision BioSciences presenting at the upcoming HC Wainwright 5th Annual Virtual Viral Hepatitis Conference

DURHAM, NC, October 3, 2024–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company leveraging its novel proprietary ARCUS® platform to deliver in vivo gene editing therapies for sophisticated gene editing including viral gene elimination Develop, announced today that the company will be presenting at a fireside chat at HC Wainwright 5^Th Annual Virtual Conference on Viral Hepatitis to be held on October 8, 2024.

Presentation details:

Date: October 8, 2024
Time: 11:00 a.m. ET
Format: Fireside chat
Webcast registration: link

The presentation will be available on Precision's website in the Investors section under Events and Presentations at investor.precisionbiosciences.com. An archived replay will be available approximately 30 days after the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is an advanced gene editing company dedicated to Improving Life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size and their simpler structure. Key functions and differentiating features may enable ARCUS nucleases to achieve more targeted, defined therapeutic outcomes. With the help of ARCUS, the company's pipeline consists of in vivo gene editing candidates designed to provide lasting cures for a wide range of genetic and infectious diseases for which there are no adequate treatment options. For more information about Precision BioSciences, visit www.precisionbiosciences.com.

The ARCUS® platform is used to develop in vivo gene editing therapies for sophisticated gene editing including gene insertion (insertion of DNA into a gene to cause expression/add function), elimination (removal of a genome, e.g. viral DNA or mutated mitochondrial DNA) and excision (removal of a large portion of a defective gene by delivery of two ARCUS nucleases in a single AAV).

View source version on businesswire.com: https://www.businesswire.com/news/home/20241003129609/en/

Contacts

Contact for investors and media:
Naresh Tanna
Vice President of Investor Relations
[email protected]